Last reviewed · How we verify

China Resources Zizhu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

China Resources Zizhu Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mifepristone tablets Mifepristone tablets marketed Progesterone receptor antagonist Progesterone receptor (PR) Reproductive Health / Gynecology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique Hopitaux De Marseille · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for China Resources Zizhu Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). China Resources Zizhu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/china-resources-zizhu-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related